Delivery Order SPE2DB22D2206-SPE2DB25FDY76
Award Date
10/28/24
Potential Completion Date
10/29/24
Potential Value
$2.6K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, SPE2DB22D1106|SPE2DB25FDJP3, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The $3,212.70 firm fixed-price delivery order is for the supply of 4566293159 CATHFLO ACTIVASE 2 MG VIALS. The contract has an ultimate completion date of November 1, 2024 and was awarded on October 31, 2024. There is no set-aside designation specified. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare...
The federal contract award is for the delivery of CATHFLO ACTIVASE 2 MG VIALS to the Defense Logistics Agency (DLA), a defense agency. The contract has a ceiling value of $2,070.45 and is a firm fixed price delivery order. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is not set aside and was awarded on May 19, 2025, with a completion date of May 20, 2025. Amerisourcebergen Drug Corp holds a significant...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,670.36, is a delivery order for the supply of 4564750980 CATHFLO ACTIVASE 2 MG VIALS, with a period of performance through May 31, 2024. The contract has a firm fixed price pricing type and is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award, with ID SPE2DB20D1109|SPE2DB22FN81M, was issued by the Defense Logistics Agency (DLA) to the prime contractor, Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $2,466.25 firm-fixed-price delivery order is for the supply of 4556591127 units of the medication CATHFLO ACTIVASE 2 MG VIALS. The contract has an ultimate completion date of March 17, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,922.92, is a Firm Fixed Price Delivery Order for the supply of CATHFLO ACTIVASE 2 MG VIALS. The contract has an ultimate completion date of July 29, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award, with ID SPE2DB22D3301|SPE2DB25FX4CM, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract, valued at $3,212.70, is a delivery order for the supply of 4,566,174,150 units of CATHFLO ACTIVASE 2 MG VIALS. This contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a critical...
This federal contract award SPE2DB20D3101|SPE2DB25FQZU6, with a ceiling value of $3,393.60, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The award is for the delivery of CATHFLO ACTIVASE 2 MG VIALS, a pharmaceutical product. It is a firm fixed-price delivery order contract with a final completion date of January 24, 2025. The contract award is not designated as a set-aside. Amerisourcebergen Drug Corp is a major pharmaceutical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of CATHFLO ACTIVASE 2 MG VIALS. The contract has a firm fixed price of $16,902.65 and a completion date of September 18, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded this contract to provide essential medical supplies and pharmaceuticals to support military treatment facilities and other government healthcare programs. The contract is not set aside...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,679.87 delivery order contract is for the supply of CATHFLO ACTIVASE 2 MG VIALS, a pharmaceutical product. The award is not set aside and is a firm fixed-price contract type with a performance period ending on May 15, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed price of $28,484.84 and an ultimate completion date of May 23, 2025. The contract provides for the delivery of CATHFLO ACTIVASE 2 MG VIALS, a pharmaceutical product, to be performed at a location in Conshohocken, Pennsylvania. This contract is not set-aside and...